New Hope is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pilot Therapeutics' Airozin(TM), New OTC Medical Food for Dietary Management Of Asthma, Presented to International Leaders in Allergy and Immunology

WINSTON-SALEM, N.C., Nov. 11 /PRNewswire-FirstCall/ -- Floyd "Ski"
Chilton, Ph.D., president, chief executive officer and chief scientific officer of Pilot Therapeutics Holdings, Inc. (OTC Bulletin Board: PLTT), a specialty pharmaceutical company developing and commercializing a portfolio of pharmaceutical and clinically validated over-the-counter products, presented at the 24th Symposium of the Collegium Internationale Allergeologicum (CIA), held in Bermuda this week.

The Collegium is comprised of the world's most prominent basic and clinical researchers in allergy and immunology. The symposium marks the first introduction of Airozin(TM), Pilot's new medical food product for the dietary management of asthma, to the international medical and research community.

Dr. Chilton's presentation introduced the allergy and immunology community to the "Development of Airozin(TM), A Natural Formulation Clinically Optimized to Inhibit Leukotriene Biosynthesis in Humans." The development of Airozin(TM) was unique in that it applied a systematic approach to developing a safe, efficacious, natural product to regulate key metabolic pathways such as leukotriene biosynthesis. Leukotrienes have been proven to be critical in driving the inflammatory component of asthma.

Dr. Chilton presented the results of four clinical trials that showed that fatty acid content ratios and formulation within Airozin(TM) were optimized to reduce leukotriene synthesis. The conclusion of the studies demonstrated that leukotrienes can be effectively blocked in humans by optimizing the concentrations and formulation of components in a complex natural mixture administered through dietary means.

Dr. Chilton stated that, "Airozin(TM) is now proven to normalize the production of leukotrienes known to cause airway inflammation in people with asthma. This has potential to help asthma sufferers to better manage their condition."

Airozin(TM) provides a new, daily, dietary management alternative for the 20 million Americans with asthma. Additionally, Airozin(TM) fills a previously unmet consumer need for safe and effective over-the-counter asthmamanagement.

About Floyd "Ski" Chilton, Ph.D.
Dr. Chilton is widely recognized for his leading work on the role of arachidonic acid metabolism in human diseases. Prior to joining Pilot Therapeutics as president, chief executive officer and chief scientific officer in December 2000, Dr. Chilton was Director of Molecular Medicine, Professor of Physiology and Pharmacology, Professor of Internal Medicine and Professor of Biochemistry at the Wake Forest University and Johns Hopkins
School of Medicine. Dr. Chilton holds 18 issued and 25 pending patents. He has authored or co-authored over 100 scientific articles and book chapters.

About Pilot
Pilot Therapeutics Holdings, Inc. is a specialty pharmaceutical company that, through its subsidiaries, is developing and commercializing a robust pipeline of pharmaceutical product candidates and clinically validated over-the-counter (OTC) medical food products. A world leader in fatty acid metabolism, Pilot has pioneered Functional Liponomics(TM), a proprietary, state-of-the-art research platform combining fatty acid and genomic profiling,
and has used this research to develop or acquire product candidates for asthma, arthritis, coronary heart disease, cystic acne and cancer. Its lead OTC medical food product, Airozin(TM), is the first clinically proven OTC maintenance product for the dietary management of asthma, a disease that afflicts approximately 20 million Americans. Pilot is in the process of
filing an Investigational New Drug Application (IND) for its lead pharmaceutical product candidate, PLT 732 to treat elevated triglycerides associated with heart disease, diabetes, and stroke. Pilot Therapeutics Holdings, Inc.'s common stock is traded on the Over-the-Counter Bulletin Board under the ticker symbol "PLTT.OB."

Certain statements in this press release are forward-looking in nature and relate to our plans, objectives, estimates and goals. Such statements are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995 and speak only as of the date of this report. The terms "expect," "anticipate," "believe," "intend," "estimate," "plan," and "project" and similar words or expressions are intended to identify forward-looking statements. The forward-looking statements are based on current expectations, are inherently uncertain, are subject to risks, and should be viewed with caution. Our business is subject to many risks and uncertainties, including our ability to register, commercialize or license our products successfully and to promote physician and patient acceptance of our products, our need to obtain substantial additional capital to fund our operations and the progress of development, and the uncertain regulatory environment (and the resulting requirements and restrictions regarding pre-marketing approval and label and promotional claims), surrounding our lead product. These and other risks and uncertainties, many of which are described in more detail in our Annual Report on Form 10-KSB under "Risk Factors," could cause actual results and experience to differ materially from those expressed or implied by any of these forward- looking statements.

For more information about Pilot Therapeutics, visit .

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.